Latest News about Pharma/Biotech
Recent news which mentions Pharma/Biotech
What To Do After The Worst Week For Healthcare Stocks Since March 2020?
November 19, 2024
From TalkMarkets
Not-So-Big Pharma
November 16, 2024
From TalkMarkets
Cidara Therapeutics' Unique Cloudbreak Platform And Its Promise In Influenza And Oncology
November 14, 2024
From TalkMarkets
What Does the Economic Modern Family Say Now?
November 10, 2024
From TalkMarkets
Volatility Hits Large Cap Biopharma: Active Rebalancing May Be Required
November 04, 2024
From TalkMarkets
Biotech Momentum Trades For The Q4 Rally
October 29, 2024
From TalkMarkets
From TalkMarkets
Biotech Stocks Poised For Another Big Move In Q4
October 07, 2024
From TalkMarkets
Tickers
RHHBY
From TalkMarkets
Biotech Stocks : Are You A Trader Or A Longer Term Investor?
October 01, 2024
From TalkMarkets
Week In Review: Zenas Raises $259 Million In IPO
September 28, 2024
From TalkMarkets
A Biotech Breakout Will Be Led By Small Caps
September 23, 2024
From TalkMarkets
The Momentum Is Building, The Markets Are Strong - Just Don’t Chase After Extended Winners
September 22, 2024
From TalkMarkets
Week In Review: Nippon Shinyaku Signs $735 Million Deal For DMD Therapy
September 21, 2024
From TalkMarkets
Beyond QQQ: Two Nasdaq ETFs For Finding Potential Future Tech Superstars
September 20, 2024
From TalkMarkets
Psychedelic Drug Stocks +6% Last Week Vs. -13% Previous Week
September 15, 2024
From TalkMarkets
AI-Focused Drug Discovery Stocks +6% Last Week Vs. -8% Previous Week
September 15, 2024
From TalkMarkets
Cloud Stocks: Salesforce Preps To Enter Veeva’s Territory
September 14, 2024
From TalkMarkets
Time To Invest And Or Trade In Bio-Tech Stocks?
September 13, 2024
From TalkMarkets
AI-Focused Drug Discovery Stocks Portfolio -8% W/e Sept 6th
September 10, 2024
From TalkMarkets
Psychedelic Compound-Based Drug Stocks Portfolio -13% W/e Sept. 6th
September 10, 2024
From TalkMarkets
Growth At Any Price (GAAP) Is A Bad Strategy. Valuation Matters.
September 08, 2024
From TalkMarkets
Week In Review: EpimAb Sells T-Cell Engager In $635 Million Deal
September 07, 2024
From TalkMarkets
Our Psychedelic Compound-Based Clinical-Stage Drug Stocks Portfolio Was Down 16% In August
September 06, 2024
From TalkMarkets
AI-Focused Drug Discovery Stocks Portfolio Down 8% In August; Down 6.7% Yesterday Alone!
September 05, 2024
From TalkMarkets
Patchy But Still Bullish
September 02, 2024
From TalkMarkets
Market Thoughts This Labor Day Weekend
September 01, 2024
From TalkMarkets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.